With the provision of human microphysiological systems / organ-on-chip technology, Dynamic42 GmbH addresses critical points in the development of applications for many areas where chemical substances and biological compounds come into direct contact with humans or are used in products for humans. Here, we contribute to increase the validity of data obtained during pre-clinical trial phases by testing on human microphysiological organ models. Thus, results are better transferable into the human situation in clinical trial phases.
To achieve this, we offer a major advantage with many years of expertise in handling and integrating immune cells into our human microphysiological models as tissue-resident components or via the circulation within the cell culture media.
On the one hand, testing in our human microphysiological models will improve the development of compounds with less side effects for humans. On the other hand, chances of costly adjustments or even termination of studies in late-stage clinical trial phases will be reduced.
Concomitant, we strive to reduce animal experimentation by using our microphysiological systems. Due to their cellular complexity, they offer increased data validity compared to standard cell culture of individual cell types. Subsequently, animal experimentation can thus be kept at a minimal level. Further, if the development of a standard alternative test method is considered for individual applications, we would like to contribute to establish and provide solutions in those cases.